BACKGROUND: Aberrant Notch activation confers a proliferative advantage to many human tumors, including melanoma. This phase 2 trial assessed the antitumor activity of RO4929097, a gamma-secretase inhibitor of Notch signaling, with respect to the progression-free and overall survival of patients with advanced melanoma. METHODS: Chemotherapy-naive patients with metastatic melanoma of cutaneous or unknown origin were treated orally with RO4929097 at a dose of 20 mg daily 3 consecutive days per week. A 2-step accrual design was used with an interim analysis of the first 32 patients and with continuation of enrollment if 4 or more of the 32 patients responded. RESULTS: Thirty-six patients from 23 institutions were enrolled; 32 patients were evaluable. RO4929097 was well tolerated, and most toxicities were grade 1 or 2. The most common toxicities were nausea (53%), fatigue (41%), and anemia (22%). There was 1 confirmed partial response lasting 7 months, and there were 8 patients with stable disease lasting at least through week 12, with 1 of these continuing for 31 months. The 6-month progression-free survival rate was 9% (95% confidence interval [CI], 2%-22%), and the 1-year overall survival rate was 50% (95% CI, 32%-66%). Peripheral blood T-cell assays showed no significant inhibition of the production of interleukin-2, a surrogate pharmacodynamic marker of Notch inhibition, and this suggested that the drug levels were insufficient to achieve Notch target inhibition. CONCLUSIONS: RO4929097 showed minimal clinical activity against metastatic melanoma in this phase 2 trial, possibly because of inadequate exposure to therapeutic drug levels. Although Notch inhibition remains a compelling target in melanoma, the results do not support further investigation of RO4929097 with this dose and schedule.
BACKGROUND: Aberrant Notch activation confers a proliferative advantage to many human tumors, including melanoma. This phase 2 trial assessed the antitumor activity of RO4929097, a gamma-secretase inhibitor of Notch signaling, with respect to the progression-free and overall survival of patients with advanced melanoma. METHODS: Chemotherapy-naive patients with metastatic melanoma of cutaneous or unknown origin were treated orally with RO4929097 at a dose of 20 mg daily 3 consecutive days per week. A 2-step accrual design was used with an interim analysis of the first 32 patients and with continuation of enrollment if 4 or more of the 32 patients responded. RESULTS: Thirty-six patients from 23 institutions were enrolled; 32 patients were evaluable. RO4929097 was well tolerated, and most toxicities were grade 1 or 2. The most common toxicities were nausea (53%), fatigue (41%), and anemia (22%). There was 1 confirmed partial response lasting 7 months, and there were 8 patients with stable disease lasting at least through week 12, with 1 of these continuing for 31 months. The 6-month progression-free survival rate was 9% (95% confidence interval [CI], 2%-22%), and the 1-year overall survival rate was 50% (95% CI, 32%-66%). Peripheral blood T-cell assays showed no significant inhibition of the production of interleukin-2, a surrogate pharmacodynamic marker of Notch inhibition, and this suggested that the drug levels were insufficient to achieve Notch target inhibition. CONCLUSIONS: RO4929097 showed minimal clinical activity against metastatic melanoma in this phase 2 trial, possibly because of inadequate exposure to therapeutic drug levels. Although Notch inhibition remains a compelling target in melanoma, the results do not support further investigation of RO4929097 with this dose and schedule.
Authors: David W Jenkins; Sarah Ross; Margaret Veldman-Jones; Ian N Foltz; Brandon C Clavette; Kathy Manchulenko; Cath Eberlein; Jane Kendrew; Philip Petteruti; Song Cho; Melissa Damschroder; Li Peng; Dawn Baker; Neil R Smith; Hazel M Weir; David C Blakey; Vahe Bedian; Simon T Barry Journal: Mol Cancer Ther Date: 2012-06-07 Impact factor: 6.261
Authors: Ivy T Tran; Ashley R Sandy; Alexis J Carulli; Christen Ebens; Jooho Chung; Gloria T Shan; Vedran Radojcic; Ann Friedman; Thomas Gridley; Amy Shelton; Pavan Reddy; Linda C Samuelson; Minhong Yan; Christian W Siebel; Ivan Maillard Journal: J Clin Invest Date: 2013-04 Impact factor: 14.808
Authors: Edward L Korn; Ping-Yu Liu; Sandra J Lee; Judith-Anne W Chapman; Donna Niedzwiecki; Vera J Suman; James Moon; Vernon K Sondak; Michael B Atkins; Elizabeth A Eisenhauer; Wendy Parulekar; Svetomir N Markovic; Scott Saxman; John M Kirkwood Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Gwendolyn T Wong; Denise Manfra; Frederique M Poulet; Qi Zhang; Hubert Josien; Thomas Bara; Laura Engstrom; Maria Pinzon-Ortiz; Jay S Fine; Hu-Jung J Lee; Lili Zhang; Guy A Higgins; Eric M Parker Journal: J Biol Chem Date: 2004-01-06 Impact factor: 5.157
Authors: Jonathan R Strosberg; Timothy Yeatman; Jill Weber; Domenico Coppola; Michael J Schell; Gang Han; Khaldoun Almhanna; Richard Kim; Tiffany Valone; Helen Jump; Dan Sullivan Journal: Eur J Cancer Date: 2012-03-23 Impact factor: 9.162
Authors: Tyler R McCaw; Evelyn Inga; Herbert Chen; Renata Jaskula-Sztul; Vikas Dudeja; James A Bibb; Bin Ren; J Bart Rose Journal: Oncologist Date: 2021-01-02
Authors: Dareen M Mikheil; Kirthana Prabhakar; Ayyan Arshad; Carlos I Rodriguez; Michael A Newton; Vijayasaradhi Setaluri Journal: Pigment Cell Melanoma Res Date: 2019-02-03 Impact factor: 4.693
Authors: Katherine M Morgan; Bruce S Fischer; Francis Y Lee; Jamie J Shah; Joseph R Bertino; Jeffrey Rosenfeld; Amartya Singh; Hossein Khiabanian; Sharon R Pine Journal: Mol Cancer Ther Date: 2017-10-04 Impact factor: 6.261
Authors: Jorge E Gómez-Galeno; Cecilia Hurtado; Jiongjia Cheng; Ceren Yardimci; Mark Mercola; John R Cashman Journal: Bioorg Med Chem Lett Date: 2018-09-05 Impact factor: 2.823